Editorial |

A Promising Step Forward in Psoriasis Therapy

Robert S. Stern, MD
JAMA. 2003;290(23):3133-3135. doi:10.1001/jama.290.23.3133.
Text Size: A A A
Published online


About 4.5 million adults in the United States have psoriasis,1 a chronic, often uncomfortable and disfiguring disease typically lasting more than 30 years. Approximately half a million individuals find the disease a substantial problem in everyday life. Fewer than half of those affected by psoriasis find their treatment highly satisfactory.1

Although available treatment options for patients with severe psoriasis have changed little over nearly 20 years, psoriasis has recently become a focus for innovative therapies. With the development of monoclonal antibodies that alter immune function, 4 new products—2 antibodies that modulate T-cell functions (efalizumab and alefacept) and 2 tumor necrosis factor α inhibitors (infliximab and etanercept)—have demonstrated beneficial effects on moderate to severe psoriasis. In this issue of THE JOURNAL, Gordon et al2 report on the effect of efalizumab on psoriasis as measured by both physician and patient assessment. This and other studies demonstrate that efalizumab is superior to placebo.24 To determine the place of efalizumab in the current therapeutic armamentarium, however, its safety and efficacy must be determined relative to other therapies for severe psoriasis.



Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 23

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles
Treatment of recalcitrant erythrodermic psoriasis with ustekinumab. Eur J Dermatol Published online Apr 11, 2014.;
A Review of CT-P13: An Infliximab Biosimilar. BioDrugs Published online Apr 11, 2014.;